Ticker HubNasdaq

HROW

Harrow, Inc. Common Stock

PHARMACEUTICAL PREPARATIONS

Latest price

$29.35+3.20%

As of Oct 26, 2026, 5:49 PM EDT · Market data by Massive

Market cap

$1.1B

Volume

499.1K

Previous close

$28.44

Day range

$28.30 – $29.48

Listed

Apr 30, 2007

Coverage

1 article

Price performance

Recent trading

5 trading days · 15-minute intervals · ET

Five-day open $27.55Latest interval $29.35

Newsroom

Latest HROW coverage

CompanyDeep DiveOct 2, 2025

Harrow’s MELT Acquisition Could Disrupt IV Sedation—But Is It The Hottest Pharma Small-Cap Buy?

Harrow Inc. targets Melt Pharma buyout to expand sedation portfolio with MELT-300, a sublingual non-IV sedative, aiming for U.S. launch and global partnerships while diversifying beyond ophthalmics.

HROW

Company overview

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 373
Headquarters: NASHVILLE, TN
CIK: 0001360214

Company website View advanced chart

SEC filings

No filing records are attached to this profile yet.

Browse EDGAR

Profile at a glance

Apr 30, 2007

Listed

373

Employees

Market data may be delayed and is provided for informational purposes only. SmallCapsDaily content is not investment advice.